Stay updated on Biomarker-Based AML Treatment Clinical Trial
Sign up to get notified when there's something new on the Biomarker-Based AML Treatment Clinical Trial page.

Latest updates to the Biomarker-Based AML Treatment Clinical Trial page
- Check5 days agoChange DetectedAdded core study sections including References, Contacts/Locations, Eligibility, Arms and Interventions, Study Design, Conditions, Study Description, Oversight, and Study Status, with Revision v3.3.3 on 2025-12-17. Earlier Revision v3.3.2 (2024-09-19) removed the HHS Vulnerability Disclosure.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedRevision history now includes a new revision v3.3.2 and removal of v3.2.0; the rest of the study record version list remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedRemoval of the government funding lapse notice from the page; the message explaining potential delays and where to check operating status is no longer shown. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check55 days agoChange DetectedThe latest version updates the study status and oversight information as of 2024-09-16, reflecting changes to the record’s status and related governance details.SummaryDifference0.1%

- Check84 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference11%

- Check91 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.3%

Stay in the know with updates to Biomarker-Based AML Treatment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker-Based AML Treatment Clinical Trial page.